Results 61 to 70 of about 279,339 (314)

Multi‐kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin‐related protein 1

Molecular Oncology, 2021
Recent studies revealed the role of dynamin‐related protein 1 (DRP1), encoded by the DNM1L gene, in regulating the growth of cancer cells of various origins. However, the regulation, function, and clinical significance of DRP1 remain undetermined in lung
Kuei‐Pin Chung, Yen‐Lin Huang, Yi‐Jung Chen, Yi‐Hsiu Juan, Chia‐Lang Hsu, Kiichi Nakahira, Yen‐Tsung Huang, Mong‐Wei Lin, Shang‐Gin Wu, Jin‐Yuan Shih, Yih‐Leong Chang, Chong‐Jen Yu   +11 more
doaj   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Expression and clinical role of in lung adenocarcinoma

Journal of International Medical Research
Objective To explore the levels of expression and clinical role of peroxiredoxin 6 ( PRDX6 ) in lung adenocarcinoma. Methods This retrospective study used a series of bioinformatics methods to detect the levels of expression of and mutations in the PRDX6
Zixin Chen, Junjun Lin, Huifang Wang, Jing Wang, Zhou Zhang   +4 more
doaj   +1 more source

Molecular biomarkers for lung adenocarcinoma [PDF]

European Respiratory Journal, 2017
The identification of oncogenic driver alterations that underlie sensitivity to small inhibitors has led to growing interest in identifying additional targetable oncogenes in nonsmall cell lung cancer. Although the therapeutic impact of the discovery of these alterations has now been widely demonstrated, the epidemiological data associated with each of
Anne Pradines, Julien Mazieres, Olivier Calvayrac, Elvire Pons, Nicolas Guibert, Nicolas Guibert   +5 more
openaire   +3 more sources

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

Impact of histopathological subtypes on invasive lung adenocarcinoma: from epidemiology to tumour microenvironment to therapeutic strategies

World Journal of Surgical Oncology
Lung adenocarcinoma is the most prevalent type of lung cancer, with invasive lung adenocarcinoma being the most common subtype. Screening and early treatment of high-risk individuals have improved survival; however, significant differences in prognosis ...
Shaowei Xin, Miaomiao Wen, Yahui Tian, Honghong Dong, Zitong Wan, Suxin Jiang, Fancheng Meng, Yanlu Xiong, Yong Han   +8 more
doaj   +1 more source

The distinctive nature of adenocarcinoma of the lung

OncoTargets and Therapy, 2015
In recent years, many personalized treatments have been developed for NSCLC (non-small-cell lung cancer) patients. Among these, gefitinib, erlotinib, and afatinib are selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for patients with EGFR gene mutations, while crizotinib and ceritinib are two new tyrosine kinase inhibitors ...
openaire   +6 more sources

Widespread rash in lung adenocarcinoma

ESMO Open, 2018
A 68-year-old man is being treated with cisplatin-pemetrexed in the first line for bone metastatic lung adenocarcinoma. There is partial response and very good tolerance with no grade 3–4 toxicities. After six cycles of doublet therapy, the patient follows on pemetrexed maintenance. Six months later, he develops a hot and itchy rash with …
José Miguel Jurado, Fernando Gálvez-Montosa, Francisco Almazan   +2 more
openaire   +2 more sources

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

HLA-G Expression in Lung Adenocarcinoma Tissues and Its Relationship with Prognosis

Zhongliu Fangzhi Yanjiu, 2018
Objective To investigate the expression of HLA-G and determine the prognostic value of HLA-G for lung adenocarcinoma. Methods The genomic alternation of HLA-G was analyzed using cBioPortal analytic tool.
ZHANG Wenlong, ZHANG Panpan, SI Jiahui, MA Yuanyuan, YANG Yue   +4 more
doaj   +1 more source